WeightWatchers CEO Sima Sistani is leaving the company after two and a half years. During that time, the company has radically altered its business model to stay competitive in the Ozempic era ...

WeightWatchers announced Friday that CEO Sima Sistani has stepped down from the job and is no longer on the company's board after 2½ years leading the weight loss company. Sistani has been ...

WeightWatchers (WW) International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board member and the former CEO of Shake Shack (SHAK), who ...

WeightWatchers CEO Sima Sistani abruptly stepped down Friday after a two-year stint that included a controversial embrace of weight-loss drugs like Ozempic and Wegovy. Sistani pushed the 61-year ...

WeightWatchers CEO Sima Sistani, who pushed the company into embracing weight-loss drugs, is leaving the position after a two-and-a-half year stint. Under Sistani, the 61-year-old company bought a ...

This expanded the Company’s offerings to include high-touch clinical weight management solutions alongside its science-backed behavioral programs,” WeightWatchers said in a press release.

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today that ...

It symobilizes a website link url. Copy Link It's been a bumpy year for WW International, the company also known as WeightWatchers. In a leadership shake-up Friday, the weight-loss company ...

Over 45% of WeightWatchers Clinic members have been denied GLP-1 medication coverage despite three authorization requests. WeightWatchers members receive compounded semaglutide within 1-3 business ...

WeightWatchers' CEO of roughly two years, Sima Sistani, is out. She helped push the company into the white-hot weight-loss drug space. Its interim chief said the company was in a critical period ...

Shares of WW International Inc., known as WeightWatchers, soared 18% Tuesday, after the weight-management company announced the addition of compounded GLP-1 obesity treatments to its offering.